Cision PR Newswire

CARsgen Presents First Clinical Data on Its In Vivo CAR-T Product Candidate CT1182

SHANGHAI, Nov. 22, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces the clinical data...

DAAN Biotherapeutics Signs Antibody Exclusive Licensing Agreement with LigaChem Biosciences for ADC (Antibody-Drug Conjugate) Therapeutic Development

SEOUL, South Korea, Feb. 13, 2025 /PRNewswire/ -- DAAN Biotherapeutics, a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies, has...

Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Ovarian Cancer of Anti-HER2 Bispecific ADC JSKN003

SUZHOU, China, Feb. 13, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase...

Polyplastics Launches New Eco-friendly PLASTRON (R) ︎LFT with Reduced Weight, Higher Rigidity, and Strong Damping

TOKYO, Feb. 13, 2025 /PRNewswire/ -- Polyplastics Co., Ltd., a global leader in engineering plastics, has launched PLASTRON (R) LFT (long fiber-reinforced thermoplastic) RA627P,...

Fujitsu to offer Fujitsu Cloud Service Generative AI Platform for secure and flexible enterprise data management

KAWASAKI, Japan, Feb. 13, 2025 /PRNewswire/ -- Fujitsu today announced the launch of the Fujitsu Cloud Service Generative AI Platform. The new service, which combines...